ENDRA Life Sciences (NASDAQ:NDRA) is a pioneering company focused on enhancing the capabilities of ultrasound technology to solve complex health problems. At its core, ENDRA aims to develop and commercialize Thermo Acoustic Enhanced UltraSound (TAEUS), a technology designed to provide clinicians with the ability to visualize tissue function and composition in ways previously possible only with CT or MRI, but at a fraction of the cost and with portability. This innovative approach opens new possibilities in diagnosing and monitoring diseases by making high-quality imaging more accessible and convenient. With projects spanning from early-stage clinical trials to partnerships aimed at integrating TAEUS into existing medical imaging workflows, ENDRA's objective is clear: to improve global health by making advanced imaging technology more affordable and widespread.